Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and ...

Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...

President Donald Trump’s pick to be U.S. surgeon general has said the nation’s medical and food systems are corrupted by ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Amitesh Rao, CEO of Leo South Asia, defines success as daily reinvention, driven by strategic depth, capability expansion, ...

Pfizer Vietnam, in collaboration with the Vietnam Association of Preventive Medicine, organised on June 3 and June 5 a series ...

Pfizer reported a strong sales performance for its antifungal drug Cresemba in the Asia Pacific and China, thanks to a ...

Nasal Sprays Market Nasal Sprays Market Shows Strong Potential Amid Health Awareness The nasal sprays market is evolving fast, driv ...

BIOSeedin Innovation Partnering Conference solidified its role as a nexus for global biopharma innovation, attracting more than 2,000 registrants from 10 countries. Senior executives and investors ...

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

Panaji: A four-year project named Project Parivartan, aiming to reduce hospital-acquired infections and curb antimicrobial resistance, is being implem.